Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor‐1 cycle
- 17 September 2007
- Vol. 29 (10) , 1029-1038
Abstract
Plasminogen activator inhibitor‐1 (PAI‐1) is a physiological inhibitor of urokinase (uPA), a serine protease known to promote cell migration and invasion. Intuitively, increased levels of PAI‐1 should be beneficial in downregulating uPA activity, particularly in cancer. By contrast, in vivo, increased levels of PAI‐1 are associated with a poor prognosis in breast cancer. This phenomenon is termed the “PAI‐1 paradox”. Many factors are responsible for the upregulation of PAI‐1 in the tumor microenvironment. We hypothesize that there is a breast cancer predisposition to a more aggressive stage when PAI‐1 is upregulated as a consequence of Metabolic Syndrome (MetS). MetS exerts a detrimental effect on the breast tumor microenvironment that supports cancer invasion. People with MetS have an increased risk of coronary heart disease, stroke, peripheral vascular disease and hyperinsulinemia. Recently, MetS has also been identified as a risk factor for breast cancer. We hypothesize the existence of the “PAI‐1 cycle”. Sustained by MetS, adipocytokines alter PAI‐1 expression to promote angiogenesis, tumor‐cell migration and procoagulant microparticle formation from endothelial cells, which generates thrombin and further propagates PAI‐1 synthesis. All of these factors culminate in a chemotherapy‐resistant breast tumor microenvironment. The PAI‐1 cycle may partly explain the PAI‐1 paradox. In this hypothesis paper, we will discuss further how MetS upregulates PAI‐1 and how an increased level of PAI‐1 can be linked to a poor prognosis. BioEssays 29:1029–1038, 2007.Keywords
This publication has 100 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Abdominal obesity and metabolic syndromeNature, 2006
- Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosisEuropean Journal of Cancer, 2005
- Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast CarcinomaClinical Cancer Research, 2004
- Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cellsExperimental Cell Research, 2004
- Both u‐PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasisInternational Journal of Cancer, 2002
- Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1Journal of Biological Chemistry, 2001
- Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitorsGene Therapy, 1999
- Protease inhibitors: Role and potential therapeutic use in human cancerEuropean Journal of Cancer, 1994
- Disruption of microtubules inhibits the stimulation of tissue plasminogen activator expression and promotes plasminogen activator inhibitor type 1 expression in human endothelial cellsExperimental Cell Research, 1992